Currently approved antiviral therapy for HCV is PEG-IFNα plus RBV for 48 weeks in genotypes 1 and 4, and for 24 weeks for genotypes 2 and 3. Acute HCV infection is usually asymptomatic and difficult in diagnosis. Occult HCV infection is a new entity that should be taken into account for the diagnosis of patients with elevated liver enzymes or liver disease of unknown aetiology. HCV infection causes many renal diseases especially membrano-proliferative glomerulonephritis type 1 which caused mostly by type II mixed cryoglobulinaemia. HCV infection especially genotype 3 carries higher risk of insulin resistance and hepatic steatosis which in turn help progression of liver diseases. HBV/HCV co-infection is not uncommon, especially within areas of high prevalence of HBV. Dual infections represent unique management challenges. This book is highlight the different treatment modalities of HCV patients in different medical conditions.